Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab (Q39070576)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 December 2016

Language	Label	Description	Also known as
English	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab	scientific article published on 22 December 2016

Statements

scholarly article

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab (English)

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

0 references

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ronald P DeMatteo

18

object named as

Ronald P DeMatteo

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Sandra P D'Angelo

1

object named as

Sandra P D'Angelo

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

5

object named as

Mrinal M Gounder

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

author name string

Alexander N Shoushtari

2

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Mary Louise Keohan

3

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Mark A Dickson

4

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Ping Chi

6

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Jennifer K Loo

7

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Leigh Gaffney

8

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Lee Schneider

9

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Zarine Patel

10

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Joseph Patrick Erinjeri

11

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Mark J Bluth

12

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Ana Sjoberg

13

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Howard Streicher

14

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Naoko Takebe

15

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Li-Xuan Qin

16

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Cristina Antonescu

17

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Richard D Carvajal

19

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

William D Tap

20

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

language of work or name

0 references

publication date

22 December 2016

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Clinical Cancer Research

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

23

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

2972-2980

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

12

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Signaling of c-kit in dendritic cells influences adaptive immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Response evaluation of gastrointestinal stromal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Immunosuppressive strategies that are mediated by tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

22 June 2018

PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

21 August 2018

SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

21 August 2018

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

21 August 2018

Lck is a key target of imatinib and dasatinib in T-cell activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

21 August 2018

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

21 August 2018

C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

21 August 2018

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5486863

2 December 2018

Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/28007774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/28007774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-16-2349

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

1 reference

Europe PubMed Central

18 June 2018

http://europepmc.org/abstract/PMC/5486863

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39070576&oldid=2101083300"